Bulletin
Investor Alert

July 1, 2021, 9:04 a.m. EDT

Novavax's experimental COVID-19 shot has 86.4% efficacy against the Alpha variant

Shares of Novavax Inc. (NAS:NVAX) were up 2.5% in premarket trading on Thursday, the day after The New England Journal of Medicine published a "final analysis" looking at how Novavax's COVID-19 vaccine candidate performed in a Phase 3 clinical trial conducted in 15,000 participants in the U.K. An earlier analysis of the data was previously published as a preprint. According to the new study, Novavax's experimental vaccine has an overall efficacy rate of 96.4% against the original strain of the virus and an 86.3% efficacy rate against the Alpha variant, which was first identified in the U.K. and has been the most dominant form of the virus in many countries since the start of the year. Novavax did not mention the Delta variant, which is now the most dominant form of the virus in the U.K., in this study. The company is conducting separate studies of its experimental shot in the U.S. Novavax's stock is up 90.4% for the year, while the broader S&P 500 (S&P:SPX) has gained 14.4%.

Link to MarketWatch's Slice.